This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bates, E. R. Articles by Grekin, R. J. Search for Related Content PubMed PubMed Citation Articles by Bates, E. R. Articles by Grekin, R. J.

Circulation, Vol 73, 1155-1161, Copyright © 1986 by American Heart Association

ARTICLES

The relationship between plasma levels of immunoreactive atrial natriuretic hormone and hemodynamic function in man

ER Bates, Y Shenker and RJ Grekin

To evaluate the relationship between plasma levels of immunoreactive atrial natriuretic hormone (IR-ANH) and different hemodynamic parameters in man, we studied 34 patients undergoing right heart catheterization. Plasma levels of IR-ANH in blood samples withdrawn from the femoral vein (n = 28), right ventricle (n = 27), and left ventricle (n = 17) were determined by radioimmunoassay. Right atrial pressure, pulmonary arterial wedge pressure, heart rate, and mean arterial pressure were found to be independent and significant predictors of IR-ANH plasma levels. The closest correlations were between right atrial pressure and either right ventricular IR-ANH levels (r = .78, p greater than .001) or femoral vein IR-ANH levels (r = .52, p less than .006). Five patients with isolated left ventricular failure had elevated IR-ANH levels out of proportion to their right atrial pressure levels. Pulmonary arterial wedge pressure also correlated with right ventricular IR-ANH levels (r = .46, p less than .002) and with femoral vein IR-ANH levels (r = .58, p less than .002). A single patient with isolated right heart failure had markedly elevated IR-ANH levels despite normal pulmonary arterial wedge pressure. Right ventricular levels were twice femoral vein levels and were closely correlated (181 +/- 40 vs 90 +/- 20 pmol/liter; r = .90, p less than .001). Right ventricular and left ventricular levels were almost identical (155 +/- 46 vs 146 +/- 43 pmol/liter; r = .99, p less than .001). Patients with volume overload states had elevated IR-ANH levels.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				G. Brancaccio, G. Michielon, R. M Di Donato, D. Costa, F. Falzea, and F. Miraldi Atrial natriuretic factor in normothermic and hypothermic cardiopulmonary bypass Perfusion, May 1, 2004; 19(3): 157 - 162. [Abstract] [PDF]

				Y. Hayashi, M. Ohtani, T. Hiraishi, and Y. Kobayashi Postoperative synthetic human atrial natriuretic peptide infusion and oral spironolactone administration for a patient with giant atria and low plasma level of atrial natriuretic peptide J. Thorac. Cardiovasc. Surg., July 1, 2002; 124(1): 206 - 209. [Full Text] [PDF]

				A. M. Richards, M. G. Nicholls, R. W. Troughton, J. G. Lainchbury, J. Elliott, C. Frampton, E. A. Espiner, I. G. Crozier, T. G. Yandle, and J. Turner Antecedent hypertension and heart failure after myocardial infarction J. Am. Coll. Cardiol., April 3, 2002; 39(7): 1182 - 1188. [Abstract] [Full Text] [PDF]

				C Briguori, S Betocchi, F Manganelli, B Gigante, M.A Losi, Q Ciampi, R Gottilla, A Violante, C.G Tocchetti, M Volpe, et al. Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy Eur. Heart J., August 1, 2001; 22(15): 1328 - 1336. [Abstract] [PDF]

				N. Hayashida, S. Chihara, H. Kashikie, E. Tayama, S. Yokose, K. Akasu, and S. Aoyagi Effects of intraoperative administration of atrial natriuretic peptide Ann. Thorac. Surg., October 1, 2000; 70(4): 1319 - 1326. [Abstract] [Full Text] [PDF]

				K. Maeda, T. Tsutamoto, A. Wada, N. Mabuchi, M. Hayashi, T. Hisanaga, T. Kamijo, and M. Kinoshita Insufficient secretion of atrial natriuretic peptide at acute phase of myocardial infarction J Appl Physiol, August 1, 2000; 89(2): 458 - 464. [Abstract] [Full Text] [PDF]

				T. Tsutamoto, A. Wada, K. Maeda, T. Hisanaga, N. Mabuchi, M. Hayashi, M. Ohnishi, M. Sawaki, M. Fujii, H. Horie, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1 Eur. Heart J., December 2, 1999; 20(24): 1799 - 1807. [Abstract] [PDF]

				C. Marie, C. Mossiat, C. Gros, J.-C. Schwartz, J.-M. Lecomte, and J. Bralet Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction Cardiovasc Res, March 1, 1999; 41(3): 544 - 553. [Abstract] [Full Text] [PDF]

				T. Hiramatsu, Y. Imai, Y. Takanashi, K. Seo, M. Terada, and M. Nakazawa Hemodynamic Effects of Human Atrial Natriuretic Peptide After Modified Fontan Procedure Ann. Thorac. Surg., March 1, 1998; 65(3): 761 - 764. [Abstract] [Full Text]

				Y.-T. Shen, R. F. Woltmann, S. Appleby, S. Prahalada, S. M. Krause, S. D. Kivilghn, R. G. Johnson, P. K. Siegl, and J. J. Lynch Lack of beneficial effects of growth hormone treatment in conscious dogs during development of heart failure Am J Physiol Heart Circ Physiol, February 1, 1998; 274(2): H456 - H466. [Abstract] [Full Text] [PDF]

				T. Tsutamoto, A. Wada, K. Maeda, T. Hisanaga, Y. Maeda, D. Fukai, M. Ohnishi, Y. Sugimoto, and M. Kinoshita Attenuation of Compensation of Endogenous Cardiac Natriuretic Peptide System in Chronic Heart Failure : Prognostic Role of Plasma Brain Natriuretic Peptide Concentration in Patients With Chronic Symptomatic Left Ventricular Dysfunction Circulation, July 15, 1997; 96(2): 509 - 516. [Abstract] [Full Text]

				K. Nishimura, K. Matsuda, S. Konno, A. Sugimoto, T. Koshiji, T. Ikeda, S. Nomoto, and T. Ban BENEFICIAL EFFECT OF SYNTHETIC HUMAN ATRIAL NATRIURETIC POLYPEPTIDE ON RENAL FUNCTION IN A PATIENT WITH GIANT ATRIA J. Thorac. Cardiovasc. Surg., April 1, 1997; 113(4): 793 - 795. [Full Text]

				C. R. Benedict, B. Shelton, D. E. Johnstone, G. Francis, B. Greenberg, M. Konstam, J. L. Probstfield, and S. Yusuf Prognostic Significance of Plasma Norepinephrine in Patients With Asymptomatic Left Ventricular Dysfunction Circulation, August 15, 1996; 94(4): 690 - 697. [Abstract] [Full Text]

				M. Gheorghiade, V. B. Hall, G. Jacobsen, M. Alam, H. Rosman, and S. Goldstein Effects of Increasing Maintenance Dose of Digoxin on Left Ventricular Function and Neurohormones in Patients With Chronic Heart Failure Treated With Diuretics and Angiotensin-Converting Enzyme Inhibitors Circulation, October 1, 1995; 92(7): 1801 - 1807. [Abstract] [Full Text]

				G. Iervasi, A. Clerico, S. Berti, A. Pilo, A. Biagini, R. Bianchi, and L. Donato Altered Tissue Degradation and Distribution of Atrial Natriuretic Peptide in Patients With Idiopathic Dilated Cardiomyopathy and Its Relationship With Clinical Severity of the Disease and Sodium Handling Circulation, April 1, 1995; 91(7): 2018 - 2027. [Abstract] [Full Text]

				H. Kawakami, T. Sumimoto, H. Matsuoka, T. Kobayashi, T. Ohtani, M. Abe, Y. Shigematsu, M. Hamada, and K. Hiwada Atrial Natriuretic Peptide and Left Atrial Systolic Function in Normal Subjects Angiology, November 1, 1993; 44(11): 903 - 907. [Abstract] [PDF]